32,000 Shares in Vaxcyte, Inc. $PCVX Bought by Allostery Investments LP

Key Points

• Allostery Investments LP has acquired a new position in Vaxcyte, purchasing 32,000 shares valued at approximately $1.2 million, representing around 1.7% of its portfolio.
• Vaxcyte's stock has an average rating of "Buy" from analysts, with a consensus price target of $130.00.
• Vaxcyte reported an adjusted EPS of ($1.22) for the last quarter, missing the consensus estimate by ($0.10).

Allostery Investments LP acquired a new position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 32,000 shares of the company's stock, valued at approximately $1,208,000. Vaxcyte comprises 1.7% of Allostery Investments LP's investment portfolio, making the stock its 16th largest holding.

Several other institutional investors also recently modified their holdings of PCVX. RA Capital Management L.P. increased its position in shares of Vaxcyte by 40.3% in the first quarter. RA Capital Management L.P. now owns 12,189,149 shares of the company's stock worth $460,262,000 after purchasing an additional 3,499,959 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Vaxcyte by 44.4% in the first quarter. Wellington Management Group LLP now owns 6,416,930 shares of the company's stock worth $242,303,000 after purchasing an additional 1,972,918 shares during the last quarter. Baker BROS. Advisors LP increased its position in shares of Vaxcyte by 1,211.0% in the first quarter. Baker BROS. Advisors LP now owns 640,885 shares of the company's stock worth $24,200,000 after purchasing an additional 592,000 shares during the last quarter. Nuveen LLC bought a new position in shares of Vaxcyte in the first quarter worth approximately $20,988,000. Finally, Paradigm Biocapital Advisors LP boosted its stake in Vaxcyte by 57.3% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,422,787 shares of the company's stock worth $116,469,000 after buying an additional 518,255 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Cowen reaffirmed a "buy" rating on shares of Vaxcyte in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to data from MarketBeat.com, Vaxcyte presently has an average rating of "Buy" and an average target price of $130.00.

Vaxcyte Trading Up 2.7%

Shares of NASDAQ:PCVX traded up $0.87 during trading on Friday, reaching $33.02. 1,375,472 shares of the company traded hands, compared to its average volume of 1,478,937. The firm has a market capitalization of $4.29 billion, a price-to-earnings ratio of -8.03 and a beta of 1.04. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $121.06. The business's fifty day moving average is $33.22 and its 200-day moving average is $40.67.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same quarter in the previous year, the firm earned ($1.10) earnings per share. On average, sell-side analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.